All‐cause mortality · people with primary hypertension
Renin inhibitors showed no clear difference in all‐cause mortality compared with ACE inhibitors (low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary hypertension in neonates
Sildenafil may leads to lower all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary hypertension in neonates
It is very uncertain whether sildenafil changes all‐cause mortality compared with active control (very low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary hypertension in neonates
Sildenafil plus iNO showed no clear difference in all‐cause mortality compared with placebo plus iNO (low certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
Long‐term mortality · all infants and children with congenital heart disease having postoperative management of pulmonary hypertension
1 finding from 1 review
Intervention not reported
Mortality 4 to 5 years · Adults with mild hypertension and no cardiovascular disease
It is very uncertain whether the intervention changes mortality 4 to 5 years (very low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with hypertension
CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · people with primary hypertension
1 finding from 1 review
Cardiovascular mortality · people with primary hypertension
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Proton pump inhibitors showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Sucralfate showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Interventions showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with proton pump inhibitors (low certainty).
1 finding from 1 review